Medikit (7749) Q2 2026 earnings summary

Executive summary

• Net sales for the six months ended September 30, 2025, rose 5.6% year-over-year to ¥11,921 million, with operating profit up 1.0% to ¥2,242 million and profit attributable to owners of parent up 5.6% to ¥1,350 million.

• Comprehensive income declined 11.1% year-over-year to ¥1,210 million for the period.

Financial highlights

• Gross profit increased to ¥4,580 million from ¥4,296 million year-over-year, while operating profit edged up to ¥2,242 million from ¥2,220 million.

• Ordinary profit rose 2.4% year-over-year to ¥2,333 million.

• Basic earnings per share improved to ¥92.40 from ¥86.40 year-over-year.

• Cash and deposits at period-end were ¥21,120 million, down from ¥21,559 million at the previous fiscal year-end.

• Net cash provided by operating activities increased to ¥2,472 million from ¥1,408 million year-over-year.

Outlook and guidance

• Full-year net sales forecast for fiscal year ending March 31, 2026, is ¥24,000 million, up 6.4% year-over-year.

• Operating profit is projected at ¥4,500 million (up 0.3%), with profit attributable to owners of parent expected to decline 3.0% to ¥2,924 million.

• Annual dividend forecast is ¥100 per share, up from ¥90 per share in the previous year.